CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced two executive promotions and appointments from within the organization. Steven Ertel has been named Executive Vice President and Chief Operating Officer; he previously held the title of Senior Vice President and Chief Business Officer. In addition, Matthew L. Sherman, M.D., has been promoted to Executive Vice President and Chief Medical Officer.
“It is my pleasure to announce Steve’s promotion to Chief Operating Officer,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron. “Steve joined Acceleron in 2006 and has been a key partner for me in making strategic decisions, building the business and running the organization. He has been the architect of all of Acceleron’s corporate partnerships, including our collaborations with Celgene, and has done a fantastic job overseeing our commercial strategy, program management, manufacturing, quality and corporate communications functions. I look forward to Steve’s continued leadership at Acceleron.”
“I am also pleased to announce the promotion of Matthew Sherman to Executive Vice President and Chief Medical Officer,” said Dr. Knopf. “Matt joined Acceleron in 2006 and immediately made key contributions such as recognizing sotatercept as a potential treatment for anemia. Since that time, Matt has built a highly productive clinical research and development organization that efficiently manages a comprehensive set of clinical trials with our most advanced programs now heading towards phase 3 clinical trials later this year. Matt is a dedicated physician scientist who recognizes the unique activities of biological agents and drives their development to clinical areas of high unmet need. I look forward to working with Matt and his outstanding clinical team to advance the company’s pipeline of innovative therapeutic candidates.”
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. For more information, please visit www.acceleronpharma.com.